NIDDM
MCID: DBT026
MIFTS: 91

Diabetes Mellitus, Noninsulin-Dependent (NIDDM)

Categories: Blood diseases, Endocrine diseases, Genetic diseases, Metabolic diseases, Neuronal diseases

Aliases & Classifications for Diabetes Mellitus, Noninsulin-Dependent

MalaCards integrated aliases for Diabetes Mellitus, Noninsulin-Dependent:

Name: Diabetes Mellitus, Noninsulin-Dependent 57 13 38 40
Type 2 Diabetes Mellitus 38 12 25 37 15
Insulin Resistance 57 29 55 6 73
Niddm 57 12 25 75 55
Diabetes Mellitus, Non-Insulin-Dependent 57 25 75 73
Noninsulin-Dependent Diabetes Mellitus 57 25 75
Insulin Resistance, Severe, Digenic 57 13 6
Diabetes Mellitus, Type 2 57 25 44
Maturity-Onset Diabetes 57 25 75
T2d 57 25 75
Hypertension, Insulin Resistance-Related, Susceptibility to 57 6
Diabetes Mellitus, Noninsulin-Dependent, Association with 57 6
Diabetes Mellitus, Type 2, Susceptibility to 57 6
Insulin Resistance, Susceptibility to 57 6
Adult-Onset Diabetes Mellitus 25 75
Diabetes Mellitus, Type Ii 57 25
Type 2 Diabetes 25 63
Diabetes Mellitus, Non-Insulin-Dependent, Susceptibility to 57
Diabetes Mellitus, Noninsulin-Dependent, Susceptibility to 57
Diabetes Mellitus, Noninsulin-Dependent, Late Onset 57
Diabetes Mellitus, Noninsulin-Dependent, Late-Onset 6
Diabetes Mellitus, Type Ii, Susceptibility to 57
Diabetes Mellitus, Noninsulin-Dependent, 2 57
Hypertension, Insulin Resistance-Related 57
Non-Insulin-Dependent Diabetes Mellitus 12
Diabetes, Type Ii, Susceptibility to 6
Diabetes, Type 2, Susceptibility to 57
Maturity-Onset Diabetes Mellitus 25
Diabetes Mellitus, Type Ii; T2d 57
Diabetes Mellitus, Adult-Onset 25
Type Ii Diabetes Mellitus 12
Diabetes Mellitus Type Ii 75
Diabetes Mellitus Type 2 75
Adult-Onset Diabetes 25
Diabetes Mellitus 73
Diabetes, Type 2 57
Type Ii Diabetes 15
Diabetes Type 2 43
Aodm 25

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant


HPO:

32
diabetes mellitus, noninsulin-dependent:
Onset and clinical course late onset
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 57 125853
Disease Ontology 12 DOID:9352
MeSH 44 D003924
NCIt 50 C26747
SNOMED-CT 68 44054006
KEGG 37 H00409
SNOMED-CT via HPO 69 263681008 48606007

Summaries for Diabetes Mellitus, Noninsulin-Dependent

MedlinePlus : 43 Diabetes means your blood glucose, or blood sugar, levels are too high. With type 2 diabetes, the more common type, your body does not make or use insulin well. Insulin is a hormone that helps glucose get into your cells to give them energy. Without insulin, too much glucose stays in your blood. Over time, high blood glucose can lead to serious problems with your heart, eyes, kidneys, nerves, and gums and teeth. You have a higher risk of type 2 diabetes if you are older, have obesity, have a family history of diabetes, or do not exercise. Having prediabetes also increases your risk. Prediabetes means that your blood sugar is higher than normal but not high enough to be called diabetes. If you are at risk for type 2 diabetes, you may be able to delay or prevent developing it by making some lifestyle changes. The symptoms of type 2 diabetes appear slowly. Some people do not notice symptoms at all. The symptoms can include Being very thirsty Urinating often Feeling very hungry or tired Losing weight without trying Having sores that heal slowly Having blurry eyesight Blood tests can show if you have diabetes. One type of test, the A1C, can also check on how you are managing your diabetes. Many people can manage their diabetes through healthy eating, physical activity, and blood glucose testing. Some people also need to take diabetes medicines. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Diabetes Mellitus, Noninsulin-Dependent, also known as type 2 diabetes mellitus, is related to maturity-onset diabetes of the young, type 1 and maturity-onset diabetes of the young, type 13, and has symptoms including tremor, angina pectoris and equilibration disorder. An important gene associated with Diabetes Mellitus, Noninsulin-Dependent is IRS1 (Insulin Receptor Substrate 1), and among its related pathways/superpathways are Cell cycle and p53 signaling pathway. The drugs Linagliptin and Metformin have been mentioned in the context of this disorder. Affiliated tissues include Pancreas and Adipose, and related phenotypes are type ii diabetes mellitus and insulin resistance

Disease Ontology : 12 A diabetes mellitus that involves high blood glucose resulting from cells fail to use insulin properly.

Genetics Home Reference : 25 Type 2 diabetes is a disorder characterized by abnormally high blood sugar levels. In this form of diabetes, the body stops using and making insulin properly. Insulin is a hormone produced in the pancreas that helps regulate blood sugar levels. Specifically, insulin controls how much glucose (a type of sugar) is passed from the blood into cells, where it is used as an energy source. When blood sugar levels are high (such as after a meal), the pancreas releases insulin to move the excess glucose into cells, which reduces the amount of glucose in the blood.

UniProtKB/Swiss-Prot : 75 Diabetes mellitus, non-insulin-dependent: A multifactorial disorder of glucose homeostasis caused by a lack of sensitivity to the body's own insulin. Affected individuals usually have an obese body habitus and manifestations of a metabolic syndrome characterized by diabetes, insulin resistance, hypertension and hypertriglyceridemia. The disease results in long-term complications that affect the eyes, kidneys, nerves, and blood vessels.

PubMed Health : 63 About type 2 diabetes: Type 2 diabetes (diabetes mellitus) is a metabolic disease that causes sugar to build up in the blood stream. The severity of diabetes can vary quite a bit: Some people only have to make minor changes to their lifestyle after they are diagnosed. Just losing a little weight and getting a bit more exercise may be enough for them to manage their diabetes. Other people who have type 2 diabetes need long-term treatment that involves taking tablets or insulin. It is then especially important for them to have a good understanding of their disease and know what they can do to stay healthy.There are two main types of diabetes. Type 1 diabetes usually develops in childhood or teenage years. This disease is a result of damage to the pancreas that leaves it producing either very little insulin or none at all.Things are different in type 2 diabetes, where insulin is made by the pancreas but the body’s cells gradually lose the ability to absorb and use the insulin. In the past, type 2 diabetes was often referred to as “adult-onset” diabetes because it is commonly diagnosed later in life. Type 2 diabetes is much more common than type 1 diabetes. About 90% of people who have diabetes have type 2 diabetes.

Description from OMIM: 125853

Related Diseases for Diabetes Mellitus, Noninsulin-Dependent

Diseases in the Diabetes Mellitus, Noninsulin-Dependent family:

Diabetes Mellitus, Noninsulin-Dependent, 1 Diabetes Mellitus, Noninsulin-Dependent, 2
Diabetes Mellitus, Noninsulin-Dependent, 3 Diabetes Mellitus, Noninsulin-Dependent, 4
Diabetes Mellitus, Noninsulin-Dependent, 5

Diseases related to Diabetes Mellitus, Noninsulin-Dependent via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 862)
# Related Disease Score Top Affiliating Genes
1 maturity-onset diabetes of the young, type 1 35.5 WFS1 SLC30A8 SLC2A2 RETN PPP1R3A PPARG
2 maturity-onset diabetes of the young, type 13 35.1 PAX4 NEUROD1 KCNJ11 HNF4A GCK ABCC8
3 maturity-onset diabetes of the young, type 6 34.9 NEUROD1 HNF4A HNF1B GCK
4 maturity-onset diabetes of the young, type 7 34.9 NEUROD1 HNF4A HNF1B GCK
5 maturity-onset diabetes of the young, type 14 34.6 ABCC8 GCK
6 renal cysts and diabetes syndrome 34.4 NEUROD1 HNF4A HNF1B GCK
7 monogenic diabetes 32.7 PAX4 KCNJ11 HNF4A GCK ABCC8
8 maturity-onset diabetes of the young, type 2 32.6 HNF4A HNF1B GCK
9 diabetes mellitus, permanent neonatal 32.4 KCNJ11 GCK ABCC8
10 diabetes mellitus 31.8 WFS1 SLC30A8 SLC2A2 RETN PPP1R3A PPARG
11 body mass index quantitative trait locus 11 31.3 SLC2A2 RETN PPARG IRS2 IRS1 INSR
12 hyperglycemia 31.1 GCGR ABCC8 SLC2A2 PPARG KCNJ11 IRS1
13 glucose intolerance 31.1 RETN PPARG IRS1 INSR GCK
14 maturity-onset diabetes of the young 30.9 SLC2A2 PAX4 NEUROD1 KCNJ11 IRS1 HNF4A
15 hyperinsulinemic hypoglycemia 30.9 KCNJ11 INSR HNF4A GCK ABCC8
16 diabetes mellitus, insulin-dependent 30.9 GCK NEUROD1 PAX4 WFS1
17 overnutrition 30.8 RETN PPARG IRS1
18 gestational diabetes 30.7 RETN KCNJ11 IRS2 IRS1 INSR HNF4A
19 maturity-onset diabetes of the young, type 3 30.7 NEUROD1 HNF4A HNF1B GCK
20 insulinoma 30.6 WFS1 SLC2A2 GCK ABCC8
21 glucose metabolism disease 30.6 SLC30A8 SLC2A2 RETN PPARG KCNJ11 IRS2
22 hypoglycemia 30.5 KCNJ11 INSR GCK AKT2 ABCC8
23 hyperinsulinism 30.4 KCNJ11 INSR HNF4A GCK ABCC8
24 maturity-onset diabetes of the young, type 4 30.4 HNF4A HNF1B GCK
25 insulin-like growth factor i 30.4 IRS2 IRS1 INSR AKT2
26 fatty liver disease 30.3 INSR IRS1 IRS2
27 pancreatic agenesis 30.3 ABCC8 KCNJ11 GCK
28 neonatal diabetes mellitus 30.3 SLC2A2 NEUROD1 KCNJ11 HNF1B GCK ABCC8
29 maturity-onset diabetes of the young, type 8, with exocrine dysfunction 12.9
30 maturity-onset diabetes of the young, type 9 12.9
31 maturity-onset diabetes of the young, type 10 12.8
32 insulin-resistant acanthosis nigricans, type a 12.8
33 maturity-onset diabetes of the young, type 11 12.7
34 fanconi renotubular syndrome 4 with maturity-onset diabetes of the young 12.7
35 diabetes mellitus, noninsulin-dependent, 1 12.7
36 diabetes mellitus, noninsulin-dependent, 5 12.7
37 pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities 12.7
38 diabetes mellitus, noninsulin-dependent, 2 12.6
39 diabetes mellitus, noninsulin-dependent, 4 12.6
40 diabetes mellitus, noninsulin-dependent, 3 12.6
41 diabetes mellitus, insulin-resistant, with acanthosis nigricans 12.5
42 insulin-resistance type b 12.5
43 intrauterine growth restriction-short stature-early adult-onset diabetes syndrome 12.3
44 hair-an syndrome 12.2
45 pseudoacromegaly with severe insulin resistance 12.2
46 insr-related severe syndromic insulin resistance 12.2
47 severe early-onset obesity-insulin resistance syndrome due to sh2b1 deficiency 12.2
48 microcephalic primordial dwarfism-insulin resistance syndrome 12.2
49 short fifth metacarpals-insulin resistance syndrome 12.2
50 short syndrome 12.0

Comorbidity relations with Diabetes Mellitus, Noninsulin-Dependent via Phenotypic Disease Network (PDN):


Acute Cystitis Decubitus Ulcer
Deficiency Anemia Familial Atrial Fibrillation
Heart Disease Hypertension, Essential
Ischemic Heart Disease Peripheral Vascular Disease
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Diabetes Mellitus, Noninsulin-Dependent:



Diseases related to Diabetes Mellitus, Noninsulin-Dependent

Symptoms & Phenotypes for Diabetes Mellitus, Noninsulin-Dependent

Symptoms via clinical synopsis from OMIM:

57
Lab:
insulin resistance
decreased glucose disposal

Endo:
noninsulin-dependent diabetes mellitus

Misc:
late onset


Clinical features from OMIM:

125853

Human phenotypes related to Diabetes Mellitus, Noninsulin-Dependent:

32
# Description HPO Frequency HPO Source Accession
1 type ii diabetes mellitus 32 HP:0005978
2 insulin resistance 32 HP:0000855
3 decreased waist to hip ratio 32 HP:0031820

UMLS symptoms related to Diabetes Mellitus, Noninsulin-Dependent:


tremor, angina pectoris, equilibration disorder, symptoms

GenomeRNAi Phenotypes related to Diabetes Mellitus, Noninsulin-Dependent according to GeneCards Suite gene sharing:

26 (show all 14)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.95 IRS2
2 Decreased viability GR00106-A-0 10.95 GPD2 SLC2A2
3 Decreased viability GR00173-A 10.95 MAPK8IP1
4 Decreased viability GR00221-A-1 10.95 AKT2 GCK INSR IRS1 PPARG
5 Decreased viability GR00221-A-2 10.95 GCK INSR IRS1 PPARG
6 Decreased viability GR00221-A-3 10.95 AKT2 GCK INSR PPARG
7 Decreased viability GR00221-A-4 10.95 AKT2 GCK INSR MAPK8IP1 PPARG
8 Decreased viability GR00231-A 10.95 GCK
9 Decreased viability GR00301-A 10.95 AKT2 MAPK8IP1
10 Decreased viability GR00342-S-2 10.95 IRS1
11 Decreased viability GR00342-S-3 10.95 AKT2 IRS1 MAPK8IP1
12 Decreased viability GR00402-S-2 10.95 ABCC8 AKT2 GCGR GCK GPD2 HNF1B
13 Decreased viability in esophageal squamous lineage GR00235-A 9.7 ABCC8 GCGR HNF1B HNF4A INSR MAPK8IP1
14 no effect GR00402-S-1 9.62 ABCC8 AKT2 GCGR GCK GPD2 HNF1B

MGI Mouse Phenotypes related to Diabetes Mellitus, Noninsulin-Dependent:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.3 ABCC8 AKT2 GCGR GCK GPD2 HNF1B
2 growth/size/body region MP:0005378 10.28 AKT2 GCGR GCK GPD2 HNF1B HNF4A
3 homeostasis/metabolism MP:0005376 10.26 ABCC8 AKT2 GCGR GCK GPD2 HNF1B
4 adipose tissue MP:0005375 10.16 AKT2 GCGR GPD2 INSR IRS1 IRS2
5 cellular MP:0005384 10.14 AKT2 GCGR HNF4A INSR IRS1 IRS2
6 behavior/neurological MP:0005386 10.13 GCGR GPD2 INSR IRS2 KCNJ11 MAPK8IP1
7 liver/biliary system MP:0005370 10 AKT2 GCGR GCK GPD2 HNF1B HNF4A
8 mortality/aging MP:0010768 9.86 AKT2 GCGR GCK GPD2 HNF1B HNF4A
9 muscle MP:0005369 9.28 AKT2 HNF1B INSR IRS1 IRS2 KCNJ11

Drugs & Therapeutics for Diabetes Mellitus, Noninsulin-Dependent

PubMedHealth treatment related to Diabetes Mellitus, Noninsulin-Dependent: 63

A number of factors influence which treatment approach for type 2 diabetes is most suitable: They include age, general physical condition, other health problems, life circumstances and personal goals.Sometimes just changing your lifestyle can have a positive effect: Losing weight and getting more exercise can make insulin more effective and lower blood sugar levels. Quitting smoking helps to reduce the risk of cardiovascular disease. Making these kinds of changes is sometimes enough to manage the condition and associated risks.If very overweight (obese) people find it hard to lose weight, surgical approaches such as stomach stapling may be an option.Some people depend on medication to regulate their blood sugar levels. The medication options include taking tablets, injecting insulin or medication called incretin mimetics (hormone-like substances that are designed to increase the body's insulin production). It's also possible to combine tablets and injections. The most common medications used to treat type 2 diabetes (antidiabetic drugs) are metformin and sulfonylureas. Newer antidiabetic drugs are also available – but there are still many unanswered questions about their effects.Depending on what other symptoms and illnesses a person has, different kinds of medication can be used to lower particular risks. For example, many people who have type 2 diabetes also have high blood pressure.The main medications that can lower the risk of cardiovascular diseaselower blood pressure (antihypertensives),prevent blood clotting (ASA, the drug in medications like Aspirin), orreduce cholesterol levels (statins).

Drugs for Diabetes Mellitus, Noninsulin-Dependent (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1002)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Linagliptin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 668270-12-0 10096344
2
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 657-24-9 14219 4091
3
Mineral oil Approved, Vet_approved Phase 4,Not Applicable 8042-47-5
4
Zinc Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 7440-66-6
5
Insulin Glargine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 160337-95-1
6
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 111025-46-8 4829
7
Exenatide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 141758-74-9 15991534
8
Saxagliptin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 361442-04-8 11243969
9
Glipizide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 29094-61-9 3478
10
Acarbose Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 56180-94-0 441184
11
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-78-2 2244
12
Liraglutide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 204656-20-2 44147092
13
Insulin Lispro Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 133107-64-9
14
Glimepiride Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 93479-97-1 3476
15
Insulin Aspart Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 116094-23-6 16132418
16
Insulin Detemir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 169148-63-4 5311023
17
Ramipril Approved Phase 4,Phase 3,Not Applicable,Early Phase 1 87333-19-5 5362129
18
Ticlopidine Approved Phase 4,Phase 2 55142-85-3 5472
19
Clopidogrel Approved Phase 4,Phase 2 113665-84-2, 120202-66-6 60606
20
Ursodeoxycholic acid Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 128-13-2 31401
21
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 64-17-5 702
22
Insulin glulisine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 207748-29-6
23
Fluvastatin Approved Phase 4,Phase 3 93957-54-1 1548972
24
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 11128-99-7, 68521-88-0, 4474-91-3 172198 65143
25
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 137862-53-4 60846
26
Alogliptin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 850649-61-5 11450633
27
Mecasermin Approved, Investigational Phase 4,Phase 2,Not Applicable 68562-41-4
28
Vildagliptin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 274901-16-5 6918537
29
Canagliflozin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 842133-18-0
30
Zaleplon Approved, Illicit, Investigational Phase 4 151319-34-5 5719
31
Gliclazide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 21187-98-4 3475
32
Clonidine Approved Phase 4,Phase 3 4205-90-7 2803
33
Furosemide Approved, Vet_approved Phase 4,Phase 1 54-31-9 3440
34
Doxazosin Approved Phase 4,Phase 3 74191-85-8 3157
35
Irbesartan Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable 138402-11-6 3749
36
Atenolol Approved Phase 4 29122-68-7 2249
37
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 79902-63-9 54454
38
Amlodipine Approved Phase 4,Phase 3,Phase 1,Not Applicable 88150-42-9 2162
39
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 58-93-5 3639
40
Fenofibrate Approved Phase 4,Phase 3,Phase 2,Not Applicable 49562-28-9 3339
41
Enalapril Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 75847-73-3 5362032 40466924
42
Enalaprilat Approved Phase 4,Phase 3,Phase 2,Not Applicable 76420-72-9 6917719
43
AT-101 Approved, Investigational Phase 4,Not Applicable 90141-22-3, 652-67-5 12597
44
Nitric Oxide Approved Phase 4,Phase 2,Phase 3,Not Applicable 10102-43-9 145068
45
Isosorbide Dinitrate Approved, Investigational Phase 4,Not Applicable 87-33-2 6883
46
Ticagrelor Approved Phase 4,Phase 3,Not Applicable 274693-27-5 9871419
47
Repaglinide Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 135062-02-1 65981
48
Glyburide Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 10238-21-8 3488
49
Testosterone enanthate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 315-37-7 9416
50
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-18-4 6010

Interventional clinical trials:

(show top 50) (show all 7653)
# Name Status NCT ID Phase Drugs
1 Effect of Linagliptin on Insulin Sensitivity and Pancreatic Beta Cell Function in Patients With Type 2 Diabetes Mellitus Unknown status NCT02097342 Phase 4 Linagliptin;Placebo;Voglibose
2 Bone Turnover in Type 2 Diabetes Patients Unknown status NCT00732121 Phase 4 Sitagliptin;Placebo
3 Continuous Glucose Monitoring in Patients With Type 2 Diabetes Unknown status NCT00529815 Phase 4
4 The Assessment of the Effect of Vitamin D Supplementation on Inflammatory and Endothelial Factors in the Patients With Type 2 Diabetes . Unknown status NCT03008057 Phase 4
5 The Effect of n-3 Fatty Acid Supplementation on Serum Levels, and Gene Expression of type2 Diabetes Patient Unknown status NCT02261545 Phase 4
6 Can Insulin Glargine Improve Myocardial Function in Patients With T2D and Coronary Artery Disease (CAD) Unknown status NCT01035528 Phase 4 insulin glargine;metformin
7 Multifactorial Intervention in Type 2 Diabetes - Italy Unknown status NCT01240070 Phase 4
8 Comparison of the Efficacy and Safety Between Pioglitazone and Placebo Added to Combination Therapy in Type 2 Diabetes Unknown status NCT00991055 Phase 4 Pioglitazone
9 Study of Comparison the Treatment Effect Between Gastric Bypass and Exenatide in Type 2 Diabetes Unknown status NCT01435980 Phase 4 Exenatide
10 Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia Unknown status NCT01267448 Phase 4 Glipizide XL;Saxagliptin + Metformin XR;Metformin XR
11 Efficacy of Acarbose on Intestinal Microbiome and Incretins of Type 2 Diabetes Unknown status NCT01758471 Phase 4 Glipizide;Acarbose
12 Type 2 Diabetes Mellitus and Atherosclerosis Unknown status NCT01250340 Phase 4 Aspirin;Placebo
13 Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes Unknown status NCT02344186 Phase 4 Liraglutide
14 Metformin and Sitagliptin Therapy for Adult Patients With Type 2 Diabetes Admitted to the General Medical Unit Unknown status NCT02250794 Phase 4 metformin and sitagliptin;insulin glargine and insulin lispro;metformin and sitagliptin;insulin glargine and insulin lispro
15 Clinical Study to Compare Various Dosing and Titration Guidelines of Insulin Delivered Via V-Go ® in Patients With Type 2 Diabetes Initiating Basal Bolus Therapy in Primary Care Offices Unknown status NCT02361489 Phase 4
16 Safety and Efficacy of Acarbose+Saxagliptin Compared With Metformin+Saxagliptin in Patients With Type 2 Diabetes Unknown status NCT02605772 Phase 4 Acarbose;Metformin;Saxagliptin
17 Mechanistic Study of the Systolic Blood Pressure Lowering Effect of Dapagliflozin in Type 2 Diabetes Unknown status NCT02372955 Phase 4 dapagliflozin;glimpiride
18 Insulin Effects on Metabolism and Cardiovascular Function in Type 2 Diabetes Unknown status NCT00747409 Phase 4 insulin aspart and detemir (NovoRapid, Levemir);human regular insulin and NPH insulin (Actrapid, Protaphne)
19 Comparison of Cardiovascular Outcomes of Pioglitazone and Metformin in Type 2 Diabetes Patients Unknown status NCT00399204 Phase 4 Pioglitazone vs Metformin
20 Ramipril and Clopidogrel in Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Type 2 Diabetes and Diabetic Nephropathy Unknown status NCT01743014 Phase 4 Ramipril;Clopidogrel
21 Effect of Victoza on Dietary Preferences and Habit in Patients With Type 2 Diabetes Unknown status NCT02674893 Phase 4 Liraglutide
22 Chronic Cold Acclimation Stimulates the Browning of Subcutaneous White Adipose in Patients With Type 2 Diabetes Mellitus Unknown status NCT02775253 Phase 4
23 Effect on Beta Cell Function and Glycaemic Control After Insulin and Exenatide Sequential Therapy Unknown status NCT02129985 Phase 4 Exenatide;Metformin
24 Efficacy and Safety of Ursodeoxycholic Acid (UDCA) Added to the DPP-4 Inhibitor in People With Type 2 Diabetes and Chronic Liver Diseases Unknown status NCT01337440 Phase 4 UDCA;Sitagliptin
25 the Effect of Vitamin D on the Serum Thioredoxin, TBP-2, Thioredoxin Reductase, Gene Expression of TBP-2 in Patients With Type II Diabetes Unknown status NCT01876563 Phase 4
26 Thyroid Study Type 2 Diabetes Mellitus (T2DM) Unknown status NCT01379170 Phase 4 Euthyrox (levothyroxine)
27 Prospective Randomized Trials of Gastric Bypass Surgery in Patients With Type II Diabetes Mellitus Unknown status NCT00540462 Phase 4
28 The Impact of Omega-3 Supplementation on Gene Expression in Type 2 Diabetics Unknown status NCT01478776 Phase 4
29 A Clinical Trial Analyzing Effects of Prokinetic Drug on the Blood Glucose in Patients With Type 2 Diabetes Unknown status NCT02606617 Phase 4 Mosapride;Placebo
30 German Diabetes-Diet-Intervention and Energy Restriction-Trial (DDIET) Unknown status NCT01409330 Phase 4
31 Various Insulin Regimens for Diabetic Inpatients With Cirrhosis Trial Unknown status NCT01143948 Phase 4 Glargine & Glulisine;Regular insulin;NPH & regular insulin
32 Intensive Medical Treatment for Nephropathy Caused by Type 2 Diabetes With Hypertension Unknown status NCT00407680 Phase 4 Intensive therapy Valsartan,Fluvastatin
33 Glucagon Like Peptides Receptors Expression in the Stomach of Diabetes Type 2 Unknown status NCT00473733 Phase 4
34 Comparison of Pioglitazone Versus Glimepiride in Type 2 Diabetes Inadequately Controlled With Metformin Plus Alogliptin Unknown status NCT02426294 Phase 4 Pioglitazone;Glimepiride
35 Effect of Linagliptin in Comparison With Glimepiride as Add on to Metformin on Postprandial Beta Cell Function, Postprandial Metabolism and Oxidative Stress in Patients With Type 2 Diabetes Mellitus Unknown status NCT01547104 Phase 4 Linagliptin;Glimepiride
36 Exploratory Study to Compare the Effects of Tenelia® or Januvia® on Glucose Variability in add-on to Metformin (CGMS Study) Unknown status NCT02512523 Phase 4 Teneligliptin;Sitagliptin
37 Vascular Effects of Sitagliptin in Diabetes Mellitus Unknown status NCT01096277 Phase 4 Sitagliptin;Placebo
38 Safety of Add on Aliskiren to Angiotensin Converting Enzyme Inhibitor (ACEI) and Angiotensin I Receptor Blocker (ARB) Treatment in Type 2 Diabetes With Nephropathy Unknown status NCT00949351 Phase 4 Aliskiren 300mg/d
39 Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism Unknown status NCT02721888 Phase 4 Liraglutide;MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
40 Treatment With Continuous Sub-cutaneous Insulin Infusion Via a Portable Pump Versus Discontinuous Insulin Infusion Via Multiple-injections in Type 2 Diabetes Unknown status NCT02048189 Phase 4 LEVEMIR;APIDRA
41 Short-Term Alpha Lipoic Acid Therapy for Prevention of Contrast-induced Acute Kidney Injury and Endothelial Dysfunction in Type 2 Diabetes Unknown status NCT01978405 Phase 4 Alpha lipoic acid
42 Metabolomic Variations in the Saxagliptin-Treated Type 2 Diabetes Mellitus Patients Unknown status NCT01768208 Phase 4 Saxagliptin
43 Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT) Unknown status NCT00915954 Phase 4
44 the Efficacy of Acarbose and Metformin on Blood Glucose Fluctuation When Combined With Premix Insulin Unknown status NCT02438397 Phase 4 premix insulin;metformin;Acarbose
45 Glycemic Durability After Metformin Failure Unknown status NCT02142309 Phase 4 Glimepiride;Vildagliptin;Pioglitazone;Canagliflozin
46 Evaluate the Effect of Saxagliptin on Gut Microbiota in Patients With Newly Diagnosed Type 2 Diabetes Unknown status NCT02583438 Phase 4 Saxagliptin (Bristol-Myers Squibb Company)
47 Effects of Valsartan and Aliskiren on Hemostatic Indices in Hypertensive Diabetics Unknown status NCT01095822 Phase 4 Aliskiren + Valsartan
48 Effect of Acarbose and Vildagliptin on Visceral Fat Distribution in Newly Diagnosed Type 2 Diabetes Patients Unknown status NCT02999841 Phase 4 Acarbose;Vildagliptin
49 Prospective Influence of Bedtime Insulin Glargine on Mobilization and Function of Endothelial Progenitor Cells Unknown status NCT00523393 Phase 4 Insulin Glargin;Human Insulin
50 Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes (SONATA Study) Unknown status NCT01869881 Phase 4 Anplag(Sarpogrelate);Placebo

Search NIH Clinical Center for Diabetes Mellitus, Noninsulin-Dependent

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cochrane evidence based reviews: diabetes mellitus, type 2

Genetic Tests for Diabetes Mellitus, Noninsulin-Dependent

Genetic tests related to Diabetes Mellitus, Noninsulin-Dependent:

# Genetic test Affiliating Genes
1 Insulin Resistance 29

Anatomical Context for Diabetes Mellitus, Noninsulin-Dependent

MalaCards organs/tissues related to Diabetes Mellitus, Noninsulin-Dependent:

41
Liver, Endothelial, Heart, Ovary, Kidney, Testes, Bone
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Diabetes Mellitus, Noninsulin-Dependent:
# Tissue Anatomical CompartmentCell Relevance
1 Pancreas Islets of Langerhans Mature Beta Cells Affected by disease, potential therapeutic candidate
2 Adipose Subcutaneous White Adipose Mesenchymal Stem Cells Potential therapeutic candidate
3 Adipose Subcutaneous White Adipose Stromal Cells Potential therapeutic candidate

Publications for Diabetes Mellitus, Noninsulin-Dependent

Articles related to Diabetes Mellitus, Noninsulin-Dependent:

(show top 50) (show all 5190)
# Title Authors Year
1
Higher hemoglobin A1C and atherogenic lipoprotein profiles in children and adolescents with type 2 diabetes mellitus. ( 30547005 )
2019
2
One quarter of total myocardial infarctions are silent manifestation in patients with type 2 diabetes mellitus. ( 30487058 )
2019
3
Punicic acid: A potential compound of pomegranate seed oil in Type 2 diabetes mellitus management. ( 30317607 )
2019
4
ERα and/or ERβ activation ameliorates cognitive impairment, neurogenesis and apoptosis in type 2 diabetes mellitus mice. ( 30201537 )
2019
5
Evolution of type 2 diabetes mellitus treatment approaches. ( 30204296 )
2019
6
Efficacy of different antidiabetic drugs based on metformin in the treatment of type 2 diabetes mellitus: A network meta-analysis involving eight eligible randomized-controlled trials. ( 30145806 )
2019
7
Expression of inflammasome complex mRNA and its targeted microRNA in type 2 diabetes mellitus: A possible predictor of the severity of diabetic nephropathy. ( 30151904 )
2019
8
Changes in CDKN2A/2B expression associate with T-cell phenotype modulation in atherosclerosis and type 2 diabetes mellitus. ( 30176239 )
2019
9
Long-term cost-effectiveness of a Patient Empowerment Programme for type 2 diabetes mellitus in primary care. ( 30058268 )
2019
10
Toll-Like Receptor 2 (TLR-2) Gene Polymorphisms in Type 2 Diabetes Mellitus. ( 30124003 )
2019
11
The Effects of Lactobacillus casei on Glycemic Response, Serum Sirtuin1 and Fetuin-A Levels in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial ( 29803203 )
2019
12
Assessment of association between lipoxygenase genes variants in elderly Greek population and type 2 diabetes mellitus. ( 29392977 )
2018
13
Increasing prevalence of type 2 diabetes mellitus and impact of ethnicity in north Sudan. ( 29203255 )
2018
14
Maturity-onset diabetes of the young (MODY) as a model for elucidating the multifactorial origin of type 2 diabetes mellitus. ( 29406598 )
2018
15
Role of omentin 1 and IL-6 in type 2 diabetes mellitus patients with diabetic nephropathy. ( 28864059 )
2018
16
Quality assessment of recent evidence-based clinical practice guidelines for management of type 2 diabetes mellitus in adults using the AGREE II instrument. ( 28948654 )
2018
17
The influence of prehypertension, hypertension, and glycated hemoglobin on the development of type 2 diabetes mellitus in prediabetes: the Korean Genome and Epidemiology Study (KoGES). ( 29380232 )
2018
18
The interaction between apolipoprotein B insertion/deletion polymorphism and macronutrient intake on lipid profile and serum leptin and ghrelin levels in type 2 diabetes mellitus patients. ( 29374794 )
2018
19
Osteoprotegerin concentration is associated with the presence and severity of peripheral arterial disease in type 2 diabetes mellitus. ( 29313442 )
2018
20
Incidence of type 2 diabetes mellitus and hyperlipidemia in patients prescribed dasatinib or nilotinib as first- or second-line therapy for chronic myelogenous leukemia in the US. ( 29095654 )
2018
21
Pulse pressure amplification and cardiac autonomic dysfunction in patients with type 2 diabetes mellitus. ( 29789692 )
2018
22
Barriers to insulin initiation in elderly patients with type 2 diabetes mellitus in Brazil. ( 28864058 )
2018
23
CD36 gene variants is associated with type 2 diabetes mellitus through the interaction of obesity in rural Chinese adults. ( 29572193 )
2018
24
Different Indexes of Glycemic Variability as Identifiers of Patients with Risk of Hypoglycemia in Type 2 Diabetes Mellitus. ( 29451006 )
2018
25
Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with statins. ( 29217412 )
2018
26
Combined creatinine-cystatin C CKD-EPI equation significantly underestimates measured glomerular filtration rate in people with type 2 diabetes mellitus. ( 29331592 )
2018
27
Effectiveness of vildagliptin as add-on to metformin monotherapy among uncontrolled type 2 diabetes mellitus patients in a real-world setting. ( 28418203 )
2018
28
Association between depression and persistence with oral antihyperglycemic drugs in type 2 diabetes mellitus patients in Germany. ( 29291478 )
2018
29
Individuals with Type 1 and Type 2 Diabetes Mellitus Trade Increased Hyperglycemia for Decreased Hypoglycemia When Glycemic Variability is not Improved. ( 29164512 )
2018
30
Ratio of muscle mass to fat mass assessed by bioelectrical impedance analysis is significantly correlated with liver fat accumulation in patients with type 2 diabetes mellitus. ( 29448005 )
2018
31
Vitamin D receptor gene polymorphisms among Emirati patients with type 2 diabetes mellitus. ( 28323045 )
2018
32
Hyperthyroxinemia is positively associated with prevalent and incident type 2 diabetes mellitus in two population-based samples from Northeast Germany and Denmark. ( 29239740 )
2018
33
Hepcidin, soluble transferrin receptor and IL-6 levels in obese children and adolescents with and without type 2 diabetes mellitus/impaired glucose tolerance and their association with obstructive sleep apnea. ( 29305826 )
2018
34
Exocrine pancreatic insufficiency in type 1 and type 2 diabetes mellitus: do we need to treat it? A systematic review. ( 29779830 )
2018
35
Incidence of diabetic foot ulcer in Japanese patients with type 2 diabetes mellitus: The Fukuoka diabetes registry. ( 29382584 )
2018
36
Serum fetuin-A levels in obese and non-obese subjects with and without type 2 diabetes mellitus. ( 29174342 )
2018
37
Association of circulating CTRP9 with soluble adhesion molecules and inflammatory markers in patients with type 2 diabetes mellitus and coronary artery disease. ( 29381773 )
2018
38
Hyperglycemia induced testicular damage in type 2 diabetes mellitus rats exhibiting microcirculation impairments associated with vascular endothelial growth factor decreased via PI3K/Akt pathway. ( 29435181 )
2018
39
Effect of Anagliptin on Glycemic and Lipid Profile in Patients With Type 2 Diabetes Mellitus. ( 29977423 )
2018
40
Glycemic control among primary care patients with type 2 diabetes mellitus in the Gaza Strip, Palestine. ( 29344335 )
2018
41
Restless Legs Syndrome in Iranian People With Type 2 Diabetes Mellitus: The Role in Quality of Life and Quality of Sleep. ( 29351820 )
2018
42
Comparative Characteristics of Patients with Type 2 Diabetes Mellitus Treated by Bariatric Surgery Versus Medical Treatment: a Multicentre Analysis of 277,862 Patients from the German/Austrian DPV Database. ( 29980988 )
2018
43
Role of peroxisome proliferator-activated receptor-gamma activation on visfatin, advanced glycation end products, and renal oxidative stress in obesity-induced type 2 diabetes mellitus. ( 29441829 )
2018
44
Treatment of type 2 diabetes mellitus in elderly patients. ( 29366502 )
2018
45
Matrix metalloproteinase-7 in periodontitis with type 2 diabetes mellitus. ( 29974476 )
2018
46
Assessment of vestibular-evoked myogenic potentials and video head impulse test in type 2 diabetes mellitus patients with or without polyneuropathy. ( 29330601 )
2018
47
Identification of four genes as novel susceptibility loci for early-onset type 2 diabetes mellitus, metabolic syndrome, or hyperuricemia. ( 29930802 )
2018
48
Reduced Glucose Variability With Glucose-Dependent Versus Glucose-Independent Therapies Despite Similar Glucose Control and Hypoglycemia Rates in a Randomized, Controlled Study of Older Patients With Type 2 Diabetes Mellitus. ( 29893144 )
2018
49
The effects of plasma chromium on lipid profile, glucose metabolism and cardiovascular risk in type 2 diabetes mellitus. A case - control study. ( 29975702 )
2018
50
Association between FTO gene polymorphisms and type 2 diabetes mellitus, serum levels of apelin and androgen hormones among Iranian obese women. ( 29101069 )
2018